West Pharmaceutical Services

Medical Device Manufacturing Outsourcing Market Records a Growth of USD 46.24 billion from 2022 to 2027, Major Innovations and Key Company Offerings - Technavio

Retrieved on: 
Wednesday, January 31, 2024
Robotics, Benchmark Electronics, Growth, ROW, Pressure, Electronics manufacturing services, Service, Research, USD, EMS, Jabil, Electronics, West Pharmaceutical Services, IVD, Connected space, Heraeus, Original equipment manufacturer, TE, Free, Risk management

Read a Free PDF Sample Report

Key Points: 
  • Read a Free PDF Sample Report
    Cadenceinc - The company offers medical device manufacturing outsourcing such as Cadence Device for medical device OEMs.
  • The medical device manufacturing outsourcing market share growth by the EMS segment will be significant during the forecast period.
  • Detailed information on factors that will drive the growth of the medical device manufacturing outsourcing market between 2022 and 2027.
  • Growth of the medical device manufacturing outsourcing market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of medical device manufacturing outsourcing market companies.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Sotera Health Appoints Karen Flynn to Board of Directors

Retrieved on: 
Monday, November 13, 2023
CTLT, WST, NYSE, Senior, Audit committee, Interim, University of Pennsylvania, West Pharmaceutical Services, Strategic planning, Compensation, Committee, Boston University, Catalent, Business administration, Biopharmaceutical, SHC, Compensated emancipation, University, Engineering, Management, Science

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

Key Points: 
  • CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.
  • Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry.
  • “We are excited to welcome Karen to our Board of Directors,” said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health.
  • Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company.”
    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (Nasdaq: QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent.

Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, General Health, Health, Pharmaceutical, Medical Supplies, Growth, Softgel, OTC, CDMO, Partnership, BMV, West Pharmaceutical Services

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B.

Key Points: 
  • Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B.
  • de C.V. (BMV: LABB; “Genomma”), the leading pharmaceutical and personal care company in Latin America, today announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America.
  • Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.
  • “Genomma’s strong core brands, proven business model and significant footprint throughout Latin America in the OTC market, make Genomma an ideal partner for our innovative oral delivery systems,” said Ruben Minski, CEO of Procaps Group.

Over 5,000 Shareholders and Clients Attend 30th Annual Baron Investment Conference

Retrieved on: 
Friday, November 10, 2023
Banking, Other Professional Services, Professional Services, Finance, Diamond, Baron, WST, Ronald S. Baron, KNSL, NYSE, Entrepreneurship, Beautiful Noise, FactSet, Choice Hotels, CNBC, CoStar Group, Squawk Box, Neil Diamond, Q&A, Capital, Friends, Metropolitan Opera House, Conference, FIGS, West Pharmaceutical Services, FDS, Management, Nightclub

Baron Capital held its 30th Annual Baron Investment Conference today at the Metropolitan Opera House at Lincoln Center in New York City.

Key Points: 
  • Baron Capital held its 30th Annual Baron Investment Conference today at the Metropolitan Opera House at Lincoln Center in New York City.
  • "It’s a privilege for us to host the Annual Baron Investment Conference, which gives us the opportunity to meet our clients and shareholders and introduce them to the leadership of companies in which we are invested,” said Ron Baron, Chairman, CEO, and Founder of Baron Capital.
  • Baron Capital also provides, at its own expense, entertainment in appreciation of the support of our clients and shareholders.
  • We look forward to seeing everyone back next year for the 31st Annual Baron Investment Conference."

West Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device

Retrieved on: 
Monday, December 4, 2023
WST, West Pharmaceutical Services, Society, NYSE

EXTON, Pa., Dec. 4, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.

Key Points: 
  • West expands administration systems portfolio with new smaller size needle-free admixture device for immediate use IV drug transfer designed to maximize the benefits of point-of-care nursing.
  • EXTON, Pa., Dec. 4, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.
  • The addition of the Vial2Bag Advanced® 13mm admixture device complements West's existing Vial2Bag Advanced® 20mm admixture device, with the two products providing options for the reconstitution and transfer of a drug using either a 13mm or 20mm vial and an IV bag before administration to the patient.
  • Vial2Bag Advanced® 13mm admixture device has been officially launched at Progressive Medical Inc's Booth #500 at the American Society of Health-System Pharmacists Midyear Clinical Meeting Dec. 3 through 7, in Anaheim, CA.

West to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023
WST, Conference, NYSE, West Pharmaceutical Services, Pharmaceutical industry

EXTON, Pa., Nov. 1, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at Jefferies Healthcare Conference in London, UK on Tuesday, November 14, 2023 at 10:00 AM GBT.

Key Points: 
  • EXTON, Pa., Nov. 1, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at Jefferies Healthcare Conference in London, UK on Tuesday, November 14, 2023 at 10:00 AM GBT.
  • It will also hold a fireside chat at the Stephens Annual Investment Conference in Nashville, TN on Thursday, November 16, 2023 at 8:00 AM CST.
  • A live audio webcast will be available in the "Investors" section of the Company's website at www.westpharma.com .
  • Replay of the webcasts will be available for approximately 90 days after the events.

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, Pharmaceutical, Type, Elastomer, FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Container, SCHOTT, Dätwyler, West Pharmaceutical Services, Glass, BARDA, Development, Growth, COVID-19, RTU, Duran (glass), EMA, Porta Nuova (Milan), Safety, Material, EZ, Investment, Syringe, Value proposition, Patient safety, Sterilization, Medical device, Fine chemical, Borosilicate glass, Stevanato Group

This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.

Key Points: 
  • This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.
  • It's essential to highlight that the growing demand for secure drug delivery systems has fueled the expansion of the global pharmaceutical packaging market.
  • The integration of ready-to-use (RTU) packaging containers in the pharmaceutical sector enables expedited product launches through an optimized value chain.
  • The current landscape of pre-sterilized / ready to use pharmaceutical primary packaging features close to 95 RTU containers and 85 RTU closures.

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size to Expand Lucratively and Reach $14.23 Bn to 2031 - Explained Details | Updated InsightAce Study

Retrieved on: 
Wednesday, October 25, 2023
FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Government, ATMP, SCHOTT, Dätwyler, West Pharmaceutical Services, BARDA, Development, Growth, Schott, COVID-19, RTU, Duran (glass), EMA, Nuova Cometra, SGD, Medication, Investment, Patient safety, Medical device, Beauty salon, Stevanato Group

The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.

Key Points: 
  • The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.
  • In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging.
  • The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain.
  • Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container
    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size to Expand Lucratively and Reach $14.23 Bn to 2031 - Explained Details | Updated InsightAce Study

Retrieved on: 
Wednesday, October 25, 2023
FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Government, ATMP, SCHOTT, Dätwyler, West Pharmaceutical Services, BARDA, Development, Growth, Schott, COVID-19, RTU, Duran (glass), EMA, Nuova Cometra, SGD, Medication, EZ, Investment, Patient safety, Medical device, Beauty salon, Stevanato Group

The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.

Key Points: 
  • The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.
  • In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging.
  • The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain.
  • Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container
    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure